Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C. Issue 5 (24th June 2023)

• Record Type: Journal Article
• Authors: Yang, Wenzhuo; Ge, Junliang; Yuan, Meng; Li, Jialin; Pan, Lin; Ren, Junan; Dou, Gaojing; Yang, Laiyu; Zhou, Yang; Xie, Haoqun; Wang, Xinhui; Hu, Hongrong
• Is Part Of: Anti-cancer drugs. Volume 34:Issue 5(2023)
• Page Start: 609
• Page End: 619
• Publication Date: 2023-06-24
• Subjects: inhibitor -- KRAS G12C -- lung adenocarcinoma -- virtual screening; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000001428
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Lung adenocarcinoma is one of the most aggressive and rapidly fatal types of malignant lung tumor. Molecular docking and virtual screening were effectively and systematically used to identify specific targets in malignant tumors and screen potential drugs. Here, we screen perfect leading compounds from a medicate library (ZINC15 database) and analyze their properties (conveyance, absorption, metabolism, excretion, and harmless forecasts) with potential inhibition of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C. Further results demonstrated that ZINC000013817014 and ZINC000004098458 were screened out from the ZINC15 database and were identified to have a much better binding affinity and more favorable interaction vitality binding with KRAS G12C and less rat carcinogenicity, Ames mutagenicity, way better dissolvability in water and noninhibition with cytochrome P-450 2D6. Molecular dynamics simulation analysis indicated that the binding capacity of these two compounds and KRAS G12C, ZINC000013817014-KRAS G12C, and ZINC000004098458-KRAS G12C is stable in the natural environment. Our findings reveal that ZINC000013817014 and ZINC000004098458 were perfect leading compounds to be inhibitors binding with KRAS G12C, which were selected as safe drug candidates and a cornerstone for KRAS G12C-related medicine plan and improvement. What is more, we have conducted a Cell Counting Kit-8 to verify the exactly inhibitory effects of the two selected drugs on Lung adenocarcinoma. This study establishes a solid framework for systematic anticancer medication research and development.